A Case of Metastatic Mucoepidermoid Carcinoma Complicated by Resistant Hypercalcemia

Popalzai, Muhammad; Aoun, Nelly; Baz, Walid; Mourad, Mervat; Forte, Frank; Friscia, Philip

doi:10.4137/cmo.s5733

Cited by 5 publications

(2 citation statements)

References 9 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To the best of our knowledge, there is no case report of parotid gland oncocytoma-induced hypercalcemia in the literature. However, Popalzai et al [11] reported a case of metastatic mucoepidermoid carcinoma-induced hypercalcemia.…”

Section: Discussionmentioning

confidence: 99%

Oncocytoma of the parotid gland complicated by hypercalcemia: a case report

Evren¹,

Demirbilek²,

Yiğit³

et al. 2015

Kulak Burun Bogaz Ihtis Derg

View full text Add to dashboard Cite

Salivary gland tumors are rare head and neck tumors. The majority of these tumors are benign and include pleomorphic adenoma, monomorphic adenoma, oncocytoma, and papillary cystadenoma lymphomatosum. Oncocytoma is a rare benign salivary gland tumor. In this article, we report a 69-year-old female case of oncocytoma of the right parotid gland in whom fine needle aspiration cytology result was reported as a Warthin's tumor.

show abstract

Section: Discussionmentioning

confidence: 99%

Oncocytoma of the parotid gland complicated by hypercalcemia: a case report

Evren¹,

Demirbilek²,

Yiğit³

et al. 2015

Kulak Burun Bogaz Ihtis Derg

View full text Add to dashboard Cite

show abstract

“…MEC commonly presents as a painless swelling with pressure; however, symptoms vary with tumor size and site [ 7 ]. High-grade tumors tend to metastasize to local lymph nodes, but rarely distant metastases can also occur [ 8 ]. However, even low-grade MEC has also been shown to metastasize [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Advances in the Treatment of Mucoepidermoid Carcinoma

2022

View full text Add to dashboard Cite

Mucoepidermoid carcinoma (MEC) represents 10-15% of salivary neoplasms. Due to their low incidence, it is challenging to conduct clinical trials and develop treatment guidelines. Although surgery is the most common approach for a resectable tumor, various treatment options such as chemotherapy, radiotherapy, and immunotherapy have been investigated. There is a need to implement a standardized treatment protocol to effectively manage MEC as it is a common histological subtype. Furthermore, it has become essential to assess chromosomal and genetic abnormalities recently identified with MEC, including alterations of CDKN2A , TP53 , CDKN2B , BAP1 , etc. These mutations are involved in the transformation of low-grade tumors to high-grade tumors, presenting a vital tool for evaluating the aggressive behavior of this carcinoma. Detailed immunohistochemical and translocation studies can help develop targeted therapies and monitor treatment response. Therefore, biomarker-driven research will immensely improve the outcome, especially in advanced cases. Based on thorough histology and chromosomal translocations, a more personalized treatment plan can improve the overall disease outcome. The purpose of this article is to elaborate on the current treatment advancements, particularly chemotherapy and targeted therapy, as an effective treatment modality for the management of MEC and highlight the comparison with traditional treatment approaches.

show abstract

Carboplatin/paclitaxel

2015

Reactions Weekly

View full text Add to dashboard Cite

S Carboplatin/paclitaxel Peripheral neuropathy and thrombocytopenia: case reportA 74-year-old man developed peripheral neuropathy and thrombocytopenia during treatment with carboplatin and paclitaxel [not all routes and dosages stated].The man had a history of mucoepidermoid carcinoma of parotid gland origin with distant metastases and humoral hypercalcaemia. He started receiving carboplatin and paclitaxel at a dose of 175 mg/m 2 every 3 weeks. After 4 cycles of the chemotherapy, the hypercalcaemia resolved. However, after the 6 th cycle, he developed grade IV peripheral neuropathy. Consequently, paclitaxel was withdrawn. Subsequently, after the 7 th cycle of carboplatin, he experienced thrombocytopenia [outcomes not stated ]. Carboplatin was discontinued.Author comment: "After the 6th cycle of chemotherapy, the patient developed grade IV peripheral neuropathy and as a result, paclitaxel was discontinued. After the 7th cycle of carboplatin, the patient developed thrombocytopenia necessitating withdrawal of the drug." Popalzai MJ, et al. A case of metastatic mucoepidermoid arcinoma complicated by resistant hypercalcemia. Clinical Medicine Insights: Oncology 5: 83-87, 2011. Available from: URL: http://doi.

show abstract

A Case of Metastatic Mucoepidermoid Carcinoma Complicated by Resistant Hypercalcemia

Cited by 5 publications

References 9 publications

Oncocytoma of the parotid gland complicated by hypercalcemia: a case report

Oncocytoma of the parotid gland complicated by hypercalcemia: a case report

Advances in the Treatment of Mucoepidermoid Carcinoma

Carboplatin/paclitaxel

Contact Info

Product

Resources

About